Medical Oncology

metaplastic

Questions discussed in this category

Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?

Does the metaplastic histology influence your decision-making?

1 Answer available

Papers discussed in this category

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

JAMA Oncol,

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

J Clin Oncol, 2015 Sep 28

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

JAMA, 2021 Jan 05

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

Related Topics in Medical Oncology